

# Stephen M Ansell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1297974/publications.pdf>

Version: 2024-02-01

398  
papers

9,478  
citations

61857

43  
h-index

48187

88  
g-index

399  
all docs

399  
docs citations

399  
times ranked

9939  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
2	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
3	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
4	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
5	Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 6446-6453.	3.2	297
6	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2013, 14, 1348-1356.	5.1	251
7	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
8	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
9	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
10	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	1.4	152
11	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. <i>Lancet Oncology</i> , The, 2011, 12, 361-368.	5.1	151
12	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	0.6	149
13	The immune landscape and response to immune checkpoint blockade therapy in lymphoma. <i>Blood</i> , 2020, 135, 523-533.	0.6	134
14	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
15	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
16	Hodgkin Lymphoma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1574-1583.	1.4	120
17	Non-Hodgkin Lymphoma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1152-1163.	1.4	115
18	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110

#	ARTICLE	IF	CITATIONS
19	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 2190-2199.	3.2	110
20	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
21	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97
22	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
23	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
24	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	0.6	92
25	Odronektamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. <i>Blood</i> , 2020, 136, 42-43.	0.6	87
26	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	3.2	86
27	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	2.2	86
28	Hodgkin lymphoma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 434-442.	2.0	84
29	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
30	Brentuximab vedotin. <i>Blood</i> , 2014, 124, 3197-3200.	0.6	81
31	A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. <i>Leukemia</i> , 2021, 35, 777-786.	3.3	78
32	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
33	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
34	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
35	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	0.6	68
36	Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy. <i>Mayo Clinic Proceedings</i> , 2012, 87, 571-580.	1.4	56

#	ARTICLE	IF	CITATIONS
37	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55
38	Cellular Composition of the Tumor Microenvironment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e91-e97.	1.8	53
39	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	3.2	52
40	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
41	Safety and activity of varilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 1917-1926.	2.5	51
42	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
43	<i>t(X;14)(p11;q32)</i> in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. <i>Blood</i> , 2012, 120, 3949-3957.	0.6	48
44	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.	2.8	48
45	Nivolumab in the Treatment of Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1623-1626.	3.2	45
46	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
47	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
48	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , 2017, 64, 19-27.	1.1	41
49	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
50	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
51	Targeting immune checkpoints in lymphoma. <i>Current Opinion in Hematology</i> , 2015, 22, 337-342.	1.2	38
52	Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1105-1110.	3.2	37
53	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
54	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1375-1377.	0.6	37

#	ARTICLE	IF	CITATIONS
55	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
56	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
57	Brentuximab vedotin: delivering an antimetabolic drug to activated lymphoma cells. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 99-105.	1.9	35
58	SIRP $\alpha$ expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 84.	2.8	35
59	Hodgkin lymphoma: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 1096-1103.	2.0	34
60	Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
61	Topotecan in Patients With Advanced Neuroendocrine Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 232-235.	0.6	32
62	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	0.9	32
63	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2007, 110, 121-121.	0.6	31
64	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 2700-2700.	0.6	31
65	AT101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2014, 164, 352-365.	1.2	30
66	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 467-467.	0.6	29
67	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001, 42, 1329-1337.	0.6	28
68	Hodgkin lymphoma: 2014 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 771-779.	2.0	28
69	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
70	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
71	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 955-955.	0.6	28
72	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.3	27

#	ARTICLE	IF	CITATIONS
73	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
74	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
75	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
76	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
77	Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1804-1812.	2.0	22
78	Primary central nervous system vasculitis associated with lymphoma. <i>Neurology</i> , 2018, 90, e847-e855.	1.5	22
79	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
80	High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). <i>Leukemia</i> , 2022, 36, 165-176.	3.3	22
81	Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. <i>American Journal of Hematology</i> , 2016, 91, 109-112.	2.0	20
82	Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1017-1023.	2.0	20
83	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
84	Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. <i>Cancer Treatment Reviews</i> , 2020, 88, 102042.	3.4	20
85	Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. <i>PLoS ONE</i> , 2016, 11, e0155347.	1.1	20
86	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20
87	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2015, 21, 2538-2545.	3.2	19
88	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 57.	6.9	19
89	Immunotherapy in Hodgkin Lymphoma: The Road Ahead. <i>Trends in Immunology</i> , 2019, 40, 380-386.	2.9	19
90	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4382-4382.	0.6	19

#	ARTICLE	IF	CITATIONS
91	Immune checkpoint blockade in lymphoid malignancies. <i>FEBS Journal</i> , 2016, 283, 2233-2244.	2.2	18
92	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
93	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17
94	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	6.9	17
95	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	1.2	16
96	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
97	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 21-23.	0.6	16
98	Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?. <i>Leukemia and Lymphoma</i> , 2003, 44, 1309-1315.	0.6	15
99	Serum BlyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 71-73.	2.0	15
100	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15
101	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. <i>Clinical Cancer Research</i> , 2018, 24, 6408-6420.	3.2	15
102	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
103	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
104	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. <i>Leukemia and Lymphoma</i> , 2020, 61, 298-308.	0.6	15
105	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenström Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	2.6	15
106	The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 696-700.	1.6	14
107	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14
108	CD5+ diffuse large B-cell lymphoma: a narrative review. <i>Leukemia and Lymphoma</i> , 2021, 62, 3078-3086.	0.6	14

#	ARTICLE	IF	CITATIONS
109	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <sc>T</sc> cell therapy. American Journal of Hematology, 2021, 96, E399-E402.	2.0	14
110	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. Blood, 2019, 134, 794-794.	0.6	14
111	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 104-104.	0.6	14
112	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Expert Review of Anticancer Therapy, 2016, 16, 5-12.	1.1	13
113	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. Journal of Immunology Research, 2020, 2020, 1-12.	0.9	13
114	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). Blood, 2018, 132, 679-679.	0.6	13
115	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 179-186.	0.7	12
116	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Current Treatment Options in Oncology, 2016, 17, 16.	1.3	12
117	Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leukemia and Lymphoma, 2018, 59, 221-224.	0.6	12
118	Impact of metformin use on the outcomes of newly diagnosed diffuse large B cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	1.2	12
119	Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. Leukemia Research, 2019, 81, 1-9.	0.4	12
120	Assessment of fixed duration therapies for treatment-naïve <sc>Waldenström</sc> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
121	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
122	Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. Blood, 2018, 132, 1690-1690.	0.6	12
123	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. Blood, 2018, 132, 1620-1620.	0.6	12
124	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
125	Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. F1000Research, 2017, 6, 2142.	0.8	11
126	Follicular lymphoma: watch and wait is watch and worry. Lancet Oncology, The, 2014, 15, 368-369.	5.1	10



#	ARTICLE	IF	CITATIONS
127	Tumor Microenvironment in T-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019, 176, 69-82.	0.2	10
128	Checkpoint Blockade in Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 525-533.	0.8	10
129	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	0.6	10
130	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
131	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
132	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
133	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	2.8	9
134	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021, 11, 124.	2.8	9
135	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 798-798.	0.6	9
136	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
137	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
138	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	0.8	9
139	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015, 6, 45.	0.7	8
140	Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. <i>Lancet Haematology</i> , 2019, 6, e2-e3.	2.2	8
141	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. <i>Leukemia and Lymphoma</i> , 2021, 62, 247-251.	0.6	8
142	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	1.2	8
143	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	0.8	8
144	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. <i>Blood</i> , 2005, 106, 938-938.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	0.6	8
146	Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1540-1540.	0.6	8
147	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	0.6	8
148	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
149	Hodgkin lymphoma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 851-858.	2.0	7
150	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 80.	6.9	7
151	Acalabrutinib in mantle cell lymphoma. <i>Lancet</i> , 2018, 391, 633-634.	6.3	7
152	Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2217-2222.	2.0	7
153	PD-1 Blockade in Classic Hodgkin Lymphoma. <i>JCO Oncology Practice</i> , 2021, 17, 72-73.	1.4	7
154	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 7554-7554.	0.8	7
155	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
156	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021, 96, E427-E430.	2.0	7
157	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
158	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
159	The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression. <i>Blood</i> , 2015, 126, 2661-2661.	0.6	7
160	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 649-649.	0.6	7
161	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1517-1517.	0.6	7
162	The Bone Marrow Microenvironment in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 777-786.	0.9	6

#	ARTICLE	IF	CITATIONS
163	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.2	6
164	Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1063-1074.	0.6	6
165	Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy. <i>Brain Communications</i> , 2020, 2, fcaa050.	1.5	6
166	Tigit Expression Defines a Subset of Activated Treg Cells with Prognostic Relevance in Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1590-1590.	0.6	6
167	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
168	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	0.6	6
169	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
170	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2021, 138, 2448-2448.	0.6	6
171	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
172	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
173	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1143-1156.	1.1	5
174	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	0.6	5
175	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
176	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
177	Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. <i>Investigational New Drugs</i> , 2019, 37, 9-16.	1.2	5
178	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. <i>Cancer</i> , 2020, 126, 757-764.	2.0	5
179	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , 2020, 26, 5759-5771.	3.2	5
180	Novel Therapies in the Treatment of Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 42.	1.3	5

#	ARTICLE	IF	CITATIONS
181	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	0.6	5
182	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	0.6	5
183	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma. <i>Blood</i> , 2006, 108, 2729-2729.	0.6	5
184	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010, 116, 287-287.	0.6	5
185	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	0.6	5
186	Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013, 122, 4334-4334.	0.6	5
187	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS). <i>Journal of Clinical Oncology</i> , 2018, 36, 7539-7539.	0.8	5
188	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-43.	0.6	5
189	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 5089-5092.	2.5	5
190	Current salvage therapies in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1267-1280.	0.6	5
191	Recent advances in the management of Hodgkin lymphoma. <i>F1000Research</i> , 2016, 5, 768.	0.8	4
192	Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 249-253.	1.0	4
193	Immunomodulators in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 28.	1.3	4
194	Outcomes in mantle cell lymphoma with central nervous system involvement. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	0.8	4
195	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
196	Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	2.0	4
197	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
198	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3689-3689.	0.6	4

#	ARTICLE	IF	CITATIONS
199	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 603-603.	0.6	4
200	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	0.6	4
201	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	0.6	4
202	Induction Therapy for Advanced-stage Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 75-86.	0.9	3
203	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	0.6	3
204	Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. <i>Leukemia and Lymphoma</i> , 2021, 62, 1795-1804.	0.6	3
205	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021, 11, 65.	2.8	3
206	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	1.1	3
207	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7522-7522.	0.8	3
208	CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 1036-1036.	0.7	3
209	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
210	Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 769.e1-769.e8.	0.6	3
211	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	0.6	3
212	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
213	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	0.6	3
214	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. <i>Blood</i> , 2005, 106, 2411-2411.	0.6	3
215	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. <i>Blood</i> , 2011, 118, 88-88.	0.6	3
216	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699.	0.6	3

#	ARTICLE	IF	CITATIONS
217	PD-1 Expression Defines Two Distinct T-Cell Subpopulations That Differentially Impact Patient Outcomes In Follicular Lymphoma. <i>Blood</i> , 2013, 122, 366-366.	0.6	3
218	Sustained Natural Killer Cell Recovery Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Non-Hodgkin's Lymphoma. <i>Blood</i> , 2016, 128, 4641-4641.	0.6	3
219	Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients. <i>Blood</i> , 2010, 116, 2859-2859.	0.6	3
220	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. <i>Blood</i> , 2021, 138, 2518-2518.	0.6	3
221	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3
222	Long-term outcome of immunologic autograft engineering. <i>EJHaem</i> , 2022, 3, 488-491.	0.4	3
223	Immunotransplant: Preventing Unintended Consequences. <i>Cancer Discovery</i> , 2019, 9, 1487-1489.	7.7	2
224	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
225	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19547-e19547.	0.8	2
226	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.2	2
227	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
228	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
229	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. <i>Blood</i> , 2006, 108, 234-234.	0.6	2
230	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. <i>Blood</i> , 2010, 116, 2802-2802.	0.6	2
231	Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To Waldenström's Macroglobulinemia Cells. <i>Blood</i> , 2013, 122, 1823-1823.	0.6	2
232	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T-Cell Consortium Trial. <i>Blood</i> , 2013, 122, 3044-3044.	0.6	2
233	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 124-124.	0.6	2
234	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Ibrutinib for the Treatment of Bing-Neel Syndrome. <i>Blood</i> , 2018, 132, 1609-1609.	0.6	2
236	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
237	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	0.6	2
238	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
239	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
240	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2
241	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	0.6	2
242	Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?. <i>Blood</i> , 2021, 138, 2908-2908.	0.6	2
243	Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
244	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
245	MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia. <i>Leukemia Research</i> , 2022, 116, 106841.	0.4	2
246	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CAR).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7556-7556.	0.8	2
247	Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7564-LBA7564.	0.8	2
248	Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma. <i>HemaSphere</i> , 2017, 1, e7.	1.2	1
249	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 745.	3.4	1
250	CAR T cells: Driving in the Fast Lane. <i>HemaSphere</i> , 2019, 3, e209.	1.2	1
251	Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1114-1115.	0.6	1
252	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8049-8049.	0.8	1

#	ARTICLE	IF	CITATIONS
253	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. Journal of Clinical Oncology, 2021, 39, 7542-7542.	0.8	1
254	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. Journal of Clinical Oncology, 2021, 39, 7530-7530.	0.8	1
255	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. Journal of Clinical Oncology, 2021, 39, 7555-7555.	0.8	1
256	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2018, 132, 454-454.	0.6	1
257	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. Blood, 2018, 132, 4204-4204.	0.6	1
258	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	0.6	1
259	Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era. Blood, 2019, 134, 4038-4038.	0.6	1
260	Mass Cytometry Identifies a Novel Signature for Myeloid-Derived Suppressor-Cells in Waldenstrom's Macroglobulinemia. Blood, 2019, 134, 3976-3976.	0.6	1
261	Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. Blood, 2019, 134, 4090-4090.	0.6	1
262	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	0.6	1
263	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. Blood, 2011, 118, 1640-1640.	0.6	1
264	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	0.6	1
265	Multiparametric Analysis of Intra-Tumoral T-Cells in Hodgkin's Lymphoma Using Mass Cytometry (CyTOF). Blood, 2015, 126, 1438-1438.	0.6	1
266	Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 1772-1772.	0.6	1
267	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
268	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	0.6	1
269	Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2008, 112, 1763-1763.	0.6	1
270	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. Blood, 2009, 114, 925-925.	0.6	1



#	ARTICLE	IF	CITATIONS
271	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
272	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. <i>Blood</i> , 2010, 116, 633-633.	0.6	1
273	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 143-143.	0.6	1
274	TGF- $\beta$ 2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 1586-1586.	0.6	1
275	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1
276	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. <i>Blood</i> , 2011, 118, 85-85.	0.6	1
277	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
278	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. <i>Blood</i> , 2013, 122, 245-245.	0.6	1
279	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	0.6	1
280	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
281	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
282	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
283	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleuce (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	0.6	1
284	Fundamentals of immunology for understanding immunotherapy for lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 585-589.	0.9	1
285	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
286	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
287	Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma. <i>Blood</i> , 2021, 138, 3856-3856.	0.6	1
288	Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. <i>Blood</i> , 2021, 138, 3842-3842.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	1.1	1
290	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2426-2426.	0.6	1
291	Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021, 138, 3857-3857.	0.6	1
292	Immunologic Autograft Engineering: 13 Years Follow-up. <i>Blood</i> , 2021, 138, 3936-3936.	0.6	1
293	Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1836-1836.	0.6	1
294	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 30-30.	0.6	1
295	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
296	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
297	PJP pneumonia in brentuximab vedotin recipients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19533-e19533.	0.8	1
298	Author reply: Flows and flaws in primary CNS lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	0
299	Beyond targeting malignant B cells. <i>Lancet Oncology</i> , The, 2012, 13, 657-658.	5.1	0
300	Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 921-932.	0.5	0
301	Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly. <i>Leukemia and Lymphoma</i> , 2017, 58, 2273-2274.	0.6	0
302	Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2599-2601.	0.6	0
303	Activation-induced T-cell exhaustion: too much of a good thing?. <i>Leukemia and Lymphoma</i> , 2020, 61, 255-256.	0.6	0
304	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19501-e19501.	0.8	0
305	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7558-7558.	0.8	0
306	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0

#	ARTICLE	IF	CITATIONS
307	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. Journal of Clinical Oncology, 2021, 39, e19554-e19554.	0.8	0
308	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. Blood, 2004, 104, 1397-1397.	0.6	0
309	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. Blood, 2005, 106, 4698-4698.	0.6	0
310	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution's Experience.. Blood, 2006, 108, 3062-3062.	0.6	0
311	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	0.6	0
312	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	0.6	0
313	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. Blood, 2010, 116, 3088-3088.	0.6	0
314	GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells. Blood, 2010, 116, 4125-4125.	0.6	0
315	Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2010, 116, 2705-2705.	0.6	0
316	Role of Hepcidin In Anemia of Waldenström Macroglobulinemia. Blood, 2010, 116, 4984-4984.	0.6	0
317	GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment. Blood, 2010, 116, 613-613.	0.6	0
318	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	0.6	0
319	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	0.6	0
320	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	0.6	0
321	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2862-2862.	0.6	0
322	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenström's Macroglobulinemia. Blood, 2011, 118, 770-770.	0.6	0
323	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	0.6	0
324	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. Blood, 2011, 118, 2642-2642.	0.6	0

#	ARTICLE	IF	CITATIONS
325	UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma., Blood, 2011, 118, 3691-3691.	0.6	0
326	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	0.6	0
327	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	0.6	0
328	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma., Blood, 2011, 118, 3642-3642.	0.6	0
329	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	0.6	0
330	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood, 2012, 120, 1525-1525.	0.6	0
331	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). Blood, 2012, 120, 1527-1527.	0.6	0
332	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	0.6	0
333	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	0.6	0
334	Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood, 2012, 120, 3723-3723.	0.6	0
335	Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. Blood, 2012, 120, 2688-2688.	0.6	0
336	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. Blood, 2012, 120, 2741-2741.	0.6	0
337	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	0.6	0
338	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	0.6	0
339	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. Blood, 2012, 120, 2634-2634.	0.6	0
340	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	0.6	0
341	IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. Blood, 2012, 120, 1554-1554.	0.6	0
342	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis. Blood, 2013, 122, 4287-4287.	0.6	0
344	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
345	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. Blood, 2013, 122, 1928-1928.	0.6	0
346	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	0.6	0
347	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	0.6	0
348	The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant Waldenström Macroglobulinemia. Blood, 2013, 122, 4426-4426.	0.6	0
349	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4306-4306.	0.6	0
350	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 3016-3016.	0.6	0
351	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	0.6	0
352	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	0.6	0
353	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	0.6	0
354	Signal-Regulatory Protein-1 $\alpha$ (SIRP-1 $\alpha$ ) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. Blood, 2016, 128, 2515-2515.	0.6	0
355	Inhibiting IL-2 Signaling and the Regulatory T-Cell Pathway Using Computationally Designed Novel Peptides. Blood, 2016, 128, 3875-3875.	0.6	0
356	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	0.6	0
357	Immune System Profiling of Waldenström Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	0.6	0
358	Prevalence and Regulation of Effector CD8+ T Cell Subsets in B-Cell NHL. Blood, 2018, 132, 4134-4134.	0.6	0
359	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Blood, 2018, 132, 2979-2979.	0.6	0
360	Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas. Blood, 2018, 132, 3430-3430.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Waldenström Macroglobulinemia with Excess Plasma Cells: Is it a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
362	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	0.6	0
363	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	0.6	0
364	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	0.6	0
365	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	0.6	0
366	Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 410-410.	0.6	0
367	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. Blood, 2019, 134, 1480-1480.	0.6	0
368	Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. Blood, 2019, 134, 2790-2790.	0.6	0
369	Glutathione Metabolism Contributes to the Pathobiology of Waldenstrom's Macroglobulinemia. Blood, 2019, 134, 3971-3971.	0.6	0
370	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	0.6	0
371	MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia. Blood, 2019, 134, 3966-3966.	0.6	0
372	Effect of antibiotic use prior to or concurrent with immune checkpoint inhibitors on outcomes in patients with Hodgkin lymphoma.. Journal of Clinical Oncology, 2020, 38, 8030-8030.	0.8	0
373	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation, 2021, 105, 1615-1624.	0.5	0
374	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	0.6	0
375	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFN $\gamma$ -NIS). Blood, 2021, 138, 1333-1333.	0.6	0
376	T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. Blood, 2021, 138, 3522-3522.	0.6	0
377	Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 3841-3841.	0.6	0
378	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	0.6	0

#	ARTICLE	IF	CITATIONS
379	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
380	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	0.6	0
381	Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
382	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
383	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
384	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
385	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	0.6	0
386	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
387	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	0.6	0
388	Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
389	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
390	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
391	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	0
392	Antibody therapy for non-Hodgkin's lymphoma. <i>Current Opinion in Molecular Therapeutics</i> , 2004, 6, 175-81.	2.8	0
393	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-8.	0.6	0
394	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
395	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
396	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19532-e19532.	0.8	0

#	ARTICLE	IF	CITATIONS
397	A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7586-TPS7586.	0.8	0
398	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19562-e19562.	0.8	0